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The 1.14 A˚ Crystal Structure of Yeast Cytosine
Deaminase: Evolution of Nucleotide Salvage Enzymes
and Implications for Genetic Chemotherapy
approximately 300 kDa for the active enzyme complex
(Austin and Huber, 1993a, 1993b; Ireton et al., 2001). The
bacterial enzyme is more thermostable than its yeast
counterpart (Katsuragi et al., 1987; Kievit et al., 1999;
B.L.S., unpublished data).
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the cytosine analog, 5-fluorocytosine (5FC) due to theSeattle, Washington 98109
2 Department of Pharmaceutical Sciences enzymatic conversion of 5FC to the toxic metabolite,
5-fluorouracil (5FU) (Figure 1C). This compound and itsCollege of Pharmacy
Washington State University deoxyribonucleoside, fluorodeoxyuridine (FUdR), are
potent inhibitors of DNA synthesis and are widely usedPullman, Washington 99164
in cancer treatment (Dipiro et al., 1997; Morris, 1993). In
addition, 5FU can be incorporated into RNA by salvage
pathways and interfere with RNA function. Since mostSummary
fungi express cytosine deaminase, 5FC is commonly
used as an antifungal agent (Dipiro et al., 1997).Cytosine deaminase (CD) catalyzes the deamination
Currently, cytosine deaminase is being investigatedof cytosine and is only present in prokaryotes and
for gene therapy applications against solid tumors duefungi, where it is a member of the pyrimidine salvage
to the absence of this activity in humans (Austin andpathway. The enzyme is of interest both for antimicro-
Huber, 1993a; Hirschowitz et al., 1995; Huber et al., 1993;bial drug design and gene therapy applications against
Kievit et al., 1999; Mullen et al., 1992). Mammalian cellstumors. The structure of Saccharomyces cerevisiae
genetically modified to express either the S. cerevisiaeCD has been determined in the presence and absence
or E. coli cytosine deaminase gene commit metabolicof a mechanism-based inhibitor, at 1.14 and 1.43 A˚
suicide following administration of 5FC. Because un-resolution, respectively. The enzyme forms an/ fold
transfected mammalian cells do not express CD, theysimilar to bacterial cytidine deaminase, but with no
are immune to 5FC treatment (Katsuragi et al., 1987).similarity to the / barrel fold used by bacterial cyto-
5FU is a potent antineoplastic agent in the treatmentsine deaminase or mammalian adenosine deaminase.
of colon, rectal, breast, stomach, pancreatic, and lungThe structures observed for bacterial, fungal, and
cancers. There is evidence suggesting the yeast cyto-mammalian nucleic acid deaminases represent an ex-
sine deaminase may be a better candidate for geneample of the parallel evolution of two unique protein
therapy applications due to its lower KM toward 5FCfolds to carry out the same reaction on a diverse array
(Kievit et al., 1999). The CD/5FC combination of geneof substrates.
and prodrug has been proven effective at controlling
tumor growth in animals and is currently being evaluated
Introduction in several human clinical trials (Cunningham and Nemu-
naitis, 2001; Freytag et al., 2002a, 2002b; Greco and
The pyrimidine salvage pathway enables organisms to Dachs, 2001).
utilize exogenous pyrimidine bases and nucleosides, The structure and mechanism of two separate nucleo-
which are not intermediates in de novo pyrimidine syn- side deaminases, adenosine deaminase and cytidine
thesis. Cytosine deaminase (CD; EC 3.5.4.1) catalyzes deaminase, have been well characterized through a
the deamination of cytosine to uracil and ammonia (Fig- combination of NMR and crystallographic analyses
ure 1A). Cytosine deaminase is found in bacteria and (Frick et al., 1989; Jones et al., 1989; Kurz and Frieden,
fungi, where it plays an important role in pyrimidine 1987; Mohamedali et al., 1996; Shih and Wolfenden,
salvage, but is not present in mammalian cells (Nishi- 1996; Wilson et al., 1991; Xiang et al., 1997). Although
yama et al., 1985). A comparison of Escherichia coli both utilize a catalytic zinc ion and display similar mech-
(bCD) and Saccharomyces cerevisiae (yCD) cytosine de- anisms, the two enzymes possess unrelated protein
aminases reveals significant differences between the folds and active site architectures. The reactions pro-
bacterial and fungal enzymes, including their primary ceed through the stereo-specific addition of a metal-
amino acid sequence, predicted molecular mass, qua- bound hydroxyl group to the substrate, forming a tetra-
ternary structure, and relative substrate specificities and hedral transition state intermediate that decomposes
affinities, indicating that they are distinct and separately through the elimination of ammonia (Figure 1A). For both
evolved enzymes. The yeast enzyme is a homodimer enzymes, a glutamic acid residue participates in acid-
with individual subunits comprised of 158 residues, cor- base catalysis, facilitating protonation of the pyrimidine
responding to a mass of 35 kDa per functional oligomer N3 nitrogen.
(Erbs et al., 1997; Hayden et al., 1998). In contrast, the The structure of Escherichia coli cytosine deaminase
bacterial enzyme is a hexamer with individual subunits (bCD), which acts exclusively on the pyrimidine nucleo-
comprised of 426 residues, corresponding to a mass of base, has recently been determined in the presence and
absence of the bound mechanism-based inhibitor 4-(S)-
hydroxyl-3,4-dihydropyrimidine (Ireton et al., 2002). The*Correspondence: bstoddar@fred.fhcrc.org
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and absence of a mechanism-based inhibitor (4-[R]-
hydroxyl-3,4-dihydropyrimidine, or DHP) at 1.4 and
1.14 A˚ resolution respectively, with the latter structure
representing the highest resolution structure of an
aminohydrolase to date. A structural comparison of
yeast and bacterial cytosine deaminases reveals the
enzymes have dissimilar folds, active site architectures,
and bind different catalytic metal ions. A comparison of
these enzymes therefore provides an example of two
identical enzyme activities and specificities that have
evolved independently from unique structural scaffolds.
With the structure determination of yeast cytosine
deaminase, we now have high-resolution models and
descriptions for the deamination of nucleobase and nu-
cleoside substrates by both the ()8 barrel fold (mam-
malian adenosine deaminase and bacterial cytosine de-
aminase) and by the mixed / fold (bacterial cytidine
deaminase and yeast cytosine deaminase). This pro-
vides the basis for a detailed analysis of the parallel,
convergent evolution of identical enzyme activities with
similar substrate profiles from two separate protein
folds. The structure determination of bacterial and yeast
cytosine deaminase will also permit comparisons of en-
gineered enzymes that display enhanced turnover of 5-flu-
orocytosine, from both protein fold families. Bacterial
and yeast cytosine deaminase are both under active
development for anticancer prodrug gene-therapies.
Figure 1. Cytosine Deaminase Substrates
(A) Cytosine deaminase catalyzes conversion of cytosine to uracil Results and Discussion
and ammonia. The reaction proceeds through the stereospecific
addition of a metal-bound hydroxyl group to the substrate, forming
Structure Determinationa tetrahedral transition state intermediate that decomposes through
Yeast cytosine deaminase (yCD) was expressed in E.the elimination of ammonia.
coli as an N-terminal histidine-tagged fusion construct.(B) 2-hydroxypyrimidine (also called pyrimidin-2-one in its tauto-
meric keto form) is enzymatically converted to a hydrated adduct Removal of the histidine tag was essential for enzyme
that accumulates as a mechanism-based, tightly bound active site stability and crystallization (see Experimental Proce-
inhibitor. The structure of yCD was solved in the presence of this dures). Crystals were obtained that belonged to space-
inhibitor as described in the text.
group P212121, with the asymmetric unit containing two(C) 5-fluorocytosine is also deaminated by yCD to form 5-fluoruracil,
17.5 kDa monomers related by a noncrystallographica potent cytotoxic chemotherapy agent.
2-fold axis arranged to form the physiological dimer.
The structure of selenomethionine-substituted yeast cy-
tosine deaminase was determined by the single anoma-enzyme forms an ()8 barrel structure with structural lous dispersion (SAD) method at 1.4 A˚ resolution. Inter-similarity to mammalian adenosine deaminase, a rela-
pretable main chain electron density was observed fortionship that is undetectable at the sequence level, and
all 158 residues of each yCD monomer. The structuredisplays no similarity to bacterial cytidine deaminase.
was refined to an Rwork/Rfree of 16.3/17.9, with 93% ofThe enzyme is packed into a hexameric assembly stabi-
residues within the most favored region for main chainlized by a domain-swapping interaction between the C
phi-psi angles on a Ramachandran plot (Laskowski etterminus of enzyme subunits to form a trimer of dimers.
al., 1993) and an average protein B factor of 9.3 A˚2 (TableThe active site is recessed in the mouth of the enzyme
1). The structure of native yCD with the mechanism-barrel and contains a trigonal-bipyrimidal coordinated
based inhibitor 4-(R)-hydroxyl-3,4-dihydropyrimidineiron ion that coordinates a hydroxyl nucleophile. bCD
was determined to 1.14 A˚ and refined to an Rwork/Rfree ofis dependent on iron(II) for maximum activity, as removal
11.0/15.2. The first three residues (Met-Val-Thr) of oneof the iron(II) by treatment with o-phenanthroline results
of the two monomers in the asymmetric unit were disor-in inactivation of the enzyme; activity is fully restored
dered and omitted from the final model. The quality ofby the addition of free iron(II) (Porter, 2000; Porter and
the electron density map with the final model refinedAustin, 1993). Substitution of the active site iron(II) with
against data extending to 1.14 A˚ is shown in Figure 2.zinc also restores activity, but only to approximately
10% of its maximal velocity and kcat/KM values (Porter,
2000). Substrate binding involves a significant confor- Enzyme Fold, Oligomerization, and Active Site
The yCD monomer forms a compact domain with amational change that closes the barrel channel and com-
pletely sequesters the reaction complex from solvent. mixed / topology containing a central  sheet (1–5)
with two  helices (1 and 5) on one side and four We have now solved the structure of Saccharomyces
cerevisiae (yCD) cytosine deaminase in the presence helices (2–4 and 6) on the other side of the  sheet
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Table 1. Structure Determination and Refinement
Semet-Peak DHP-Bound yCD
Data Collection
Wavelength (A˚) 0.9795 (f″) 1.00
Resolution (A˚) (outer shell) 20–1.43 (1.48–1.43) 20–1.14 (1.18–1.14)
Completeness (%) 99.9 (99.7) 92.6 (61.6)
RMerge 0.042 (0.165) 0.047 (0.283)
Average I/ (I) 27.4 (9.5) 34.3 (3.8)
Phasing power 3.3
Figure of merit/after DM 0.52/0.86
Refinement Statistics
Resolution (A˚) 20–1.43 10–1.14
Number reflections 51,872 92,220
Test set (5%) 2,594 4,610
Rcryst (%) 16.3 11.0
Rfree (%) 17.9 15.2
Rms deviations
Bonds (A˚) 0.008 0.011
Angles (A˚) 1.37 1.99
Number of protein atoms 2458 2443
Number of water molecules 391 438
Ligand atoms/bound metals 5 16/4
Average B factors (A˚2)
Protein 9.2 9.8
Waters 19.6 20.5
Ligands 8.3
(Figures 2B and 2C). There are no extended loops on the sumed to undergo motion to allow access for substrate
and binding and product release. Residues lining thesurface of the enzyme subunit. The 5 (residue 135–148)
and 6 (residue 150–156) helices are separated by a entrance to the yCD active site include Phe 114 from a
loop between 4 and 4, and Trp 152 and Ile 156, foundsingle proline residue at position 149, causing a 75bend
that redirects the6 helix back toward the enzyme active on the C-terminal 6 helix. This latter helix and its resi-
dues are conserved among cytosine (but not cytidine)site. The monomer dimensions are 26  26  42 A˚. The
yCD dimer is formed by a head-to-tail association of deaminases, and appear to be important for defining
substrate specificity for the yCD enzyme subfamily.yCD monomers and is stabilized through stacking inter-
actions of the 3 helices along the noncrystallographic Each active site contains a single catalytic zinc ion
which is tetrahedrally coordinated by a histidine located2-fold axis (Figure 2E). The dimer interface buries
1000 A˚2 out of a total of 6275 A˚2 molecular surface at the beginning of helix 2 (His 62-Zn1, 2.05 A˚), two
cysteines on helix 3 (Cys 91-Zn1, 2.28 A˚; Cys 94-Zn1,area on each monomer. The interface is mainly hy-
drophobic and includes stacking interactions between 2.31 A˚), and a single bound water molecule that is appro-
priately positioned to act as a nucleophile in the deami-identical residues within each subunit (Tyr 121A-Tyr
121B) (Figure 2A). There are also eight salt-bridge inter- nation reaction (OH21-Zn1, 1.95 A˚). In the absence of
bound substrate or inhibitor the active site of each mo-actions made between 4 residues on each monomer,
involving helix 3-loop 4-5 (two each for Asp 92A- nomer also contains a second, noncatalytic zinc atom,
which is tetrahedrally coordinated by four waters (FigureArg 125B and Arg 125A-Asp 92B), and loop 2-3-helix
6 (Arg 73A-Glu 154B and Glu 154B-Arg 73A). The over- 3). The presence of the two zinc ions was confirmed by
both simulated annealing omit maps and anomalousall dimer dimensions are 26 42 52 A˚. The quaternary
structure of yCD is completely different from that ob- difference Fourier maps. The position of the second
zinc ion and its tetrahedral coordination shell closelyserved for the most closely related available protein
structures, particularly of bacterial cytidine deaminases, resembles the position, geometry, and interactions of
the sp3-hybridized C4 carbon in the structure of an en-as described below.
A single active site is present in each enzyme subunit, zyme-bound substrate analog described below. One
bound water molecule (OH21, described above) iscomprised of residues found on structural elements (1,
2, 2, 3, 3, loop 4-4, and 6) throughout the yCD shared between the two zinc atoms, which are 3.3 A˚
apart.monomer (Figure 2D). The active sites are separated by
14 A˚ and are both adjacent to the dimer interface; no The noncatalytic zinc makes very short coordination
to two of the four coordinating water molecules. Thesecooperativity has been reported for the enzyme. The
substrate binding pocket and its bound metal ions, both waters occupy strong electron density features, with
one water sandwiched between the two zinc ions asdescribed below, are buried approximately 9 A˚ behind
the mouth of the yCD active site, and are completely described above (OH21-Zn1, 1.95 A˚; OH21-Zn2, 1.73 A˚),
and the second water within short bonding distance tosequestered from exposed solvent in both the apo-
enzyme and substrate-bound structures. Structural ele- Glu 64 (OH22-Glu 64 O2, 2.37 A˚; OH22-Zn2, 1.75 A˚).
The presence of the second zinc ion is not completelyments blocking the entrance to the active site are as-
Structure
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surprising, given that 0.5 mM zinc acetate was added pound (2HP) was used in the study of yCD reported
here.during protein expression induction, but was not ex-
pected given that zinc was not a buffer component dur- Fourier difference maps calculated using diffraction
data from native yCD crystals soaked with 2HP displaying any steps of enzyme purification or crystallization,
and since only one zinc has been found in the active strong electron density for a bound 4-(R)-hydroxyl-3,4-
dihydropyrimidine molecule (the opposite enantiomericsite of adenosine and cytidine deaminases (Carlow et
al., 1999; Johansson et al., 2002; Wilson et al., 1991). At form of that seen with bCD, see below) adjacent to the
catalytic zinc ion, accompanied by disappearance ofthis time, we assume that the presence of this bound
metal ion in the apo-enzyme probably does not reflect the second, noncatalytic zinc (Figure 4). The electron
density in these maps is consistent with the conversiona mechanistically relevant component of yCD catalysis
but rather reflects a marked affinity for a tetrahedral of the inhibitor to a hydrated adduct that accumulates as
a mechanism-based, tightly bound active site inhibitor.center at that site that is fulfilled by the presence of
exogenous zinc during protein expression. A similar, This species is produced by the addition of the metal-
bound hydroxyl to the C4 position of the pyrimidine ring.although more loosely coordinated zinc ion was also
observed in one of the crystal forms of bovine carboxy- Three residues (Trp 152, Asp 155, and Ile 156) on the
C-terminal 6 helix (noted above as being conserved inpeptidase A (Bukrinsky et al., 1998). In that study, an
additional zinc is bound to a glutamate residue and cytosine deaminase enzymes evolved with this protein
fold) are in direct contact with the inhibitor molecule.bridged to the catalytic zinc by a hydroxyl. The second
zinc acts as a competitive inhibitor, the structure mimics The position of the residues comprising the yCD active
site remain unchanged from that observed for the apo-a “substrate bound” complex. The noncatalytic zinc ob-
served in the yCD structure differs significantly from the enzyme, as the noncatalytic zinc ion and its bound water
molecules occupy similar positions in the yCD bindinginhibitory zinc bound in carboxypeptidase A in that it is
not directly liganded to any protein residues. pocket, and many of the side chains originally involved
in coordinating those atoms are hydrogen bonded to
the inhibitor.yCD Complexed with a Mechanism-Based Inhibitor
There are extensive atomic interactions made be-The yCD enzyme catalyzes the deamination of a cyto-
tween yCD side chains to every atom in the DHP ring.sine nucleobase. The reaction proceeds through the
The following represent potential hydrogen bonds be-stereo-specific addition of a hydroxyl group to the cyto-
tween yCD side chains and substrate atoms: Asp 155sine substrate at the C4 position forming a tetrahedral
O2-DHP N1, 2.71 A˚; Asn 51 N2-DHP O2, 2.91 A˚; Glytransition state that decomposes through the elimina-
63 N-DHP O2, 2.88 A˚; Glu 64 O2-DHP N3, 2.80 A˚; Glution of ammonia to form uracil. Therefore, pyrimidine
64 O1-DHP O4, 2.55 A˚; and Cys 91 N-DHP O4, 3.09 A˚.ring structures such as 2-hydroxypyrimidine, that lack
Observed hydrophobic interactions include: Ile 33 CD1-an efficient leaving group for an elimination reaction at
DHP C2, 3.26 A˚; Phe 114 CE1, Leu 88 CD2, and Cys 91C4, are bound tightly by the enzyme and trapped as
CB-DHP C5, all 4.0–4.1 A˚; Trp 152 CH2, CZ3-DHP C6,mechanism-based inhibitors with stereo-specific chiral
4.0 A˚; and Ile 156 CG2-DHP C6, 3.95 A˚. In addition,centers at the site of the addition (Figure 1). This same
the pyrimidine ring of DHP is aligned to stack with thereaction is well documented for other nucleic acid deam-
imidazole ring of His 62.inase enzymes; a similar inhibition strategy was used in
previous crystallographic studies of human adenosine
deaminase (ADA), bacterial cytidine deaminase (CDA), Structural Similarity
A search of the DALI (Holm and Sander, 1993) fold recog-and bacterial cytosine deaminase (bCD). For ADA, a
purine ribonucleoside (nebularine) was shown to be en- nition server reveals that the yCD monomer fold is struc-
turally similar to three enzymes. The closest similarityzymatically converted to 6R-hydroxyl-1,6-dihydropurine
ribonucleoside (Wilson et al., 1991); for CDA, a pyrimi- (Z score 11.3; 2.6 A˚ superposition rmsd across 116 C
carbons) is to the AICAR (5-aminoimidazole-4-carboxa-dine ribonucleoside (zebularine) was used to generate
a similar inhibited complex (Frick et al., 1989; Shih and mide-ribonucleotide) transformylase domain from avian
AICAR transformylase/inosine monophosphate cyclo-Wolfenden, 1996; Xiang et al., 1997). For bCD, the inhibi-
tor 2-hydroxypyrimidine (2HP, also called pyrimidin-2-one hydrolase (ATIC: PDB ID code 1G8M) (Greasley et al.,
2001). This enzyme shares 9% sequence identity to yCD.in its keto tautomeric form) was converted to 4-(S)-
hydroxyl-3,4-dihydropyrimidine (DHP). This same com- Also closely similar are the cytidine deaminase folds
Figure 2. The Structure of Yeast Cytosine Deaminase
(A) Stereo view of SigmaA-weighted 2Fo-Fc electron density (blue) contoured at 2.5 superimposed on the final refined yCD-substrate bound
model showing interactions at the dimer interface (red, green).
(B) Stereo view of the yCD monomer C trace with every tenth residue labeled.
(C) yCD monomer ribbon diagram in the same orientation as in (B) showing a mixed / fold, with  helices colored green,  strands colored
blue, and random coil in yellow. The catalytic Zn2 ion is shown as a sphere (violet). A second Zn2 ion is located adjacent to the catalytic
zinc (data not shown).
(D) yCD monomer ribbon diagram in gray with the position of residues involved in substrate coordination colored blue, and side chains are
shown for the catalytic residue Glu 64, and His 62, Cys 91, Cys 94 coordinating the catalytic zinc (violet).
(E) On left, top view of the yCD dimer interface, and rotated 90 (right) showing the 3 stacking helices at the dimer interface. The figure was
prepared with XtalView, Raster3D, and PyMOL (DeLano, 2002; McRee, 1999; Merritt and Bacon, 1997).
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The structural similarity of the yCD monomer to the
bacterial cytidine deaminase monomers noted above
does not extend to the packing and architecture of the
functional oligomers. B. subtilis CDA is a homotetra-
meric enzyme, while E. coli CDA is a homodimer. In the
E. coli CDA structure, a pseudotetramer is formed in
which two catalytic subunits are associated with two
structurally homologous, noncatalytic domains lacking
bound zinc, proposed to be the result of a domain dupli-
cation (Betts et al., 1994). The packing and relative orien-
tation of subunits in the CDA tetramers is similar, giving
an overall rmsd of 1.7 A˚ for superimposed C atoms
from the four subunits (Johansson et al., 2002). In con-
trast, the complete yCD dimer cannot be superimposed
on any combination of two subunits in the cytidine de-
aminase structures. Although mutually orthogonal non-
crystallographic symmetry operators generate both the
yCD dimer and the bacterial CDA oligomers, the position
of these axes with respect to the enzyme subunits are
different, leading to the subunit interfaces being cen-
tered around different structural elements.
Structural Comparison to Cytidine Deaminase
The active site architecture of yCD is very similar to that
reported for E. coli and B. subtilis cytidine deaminase
(CDA) (Figure 5B), with a highly conserved motif of resi-
dues involved in metal coordination and substrate pro-
tonation (His/Cys-X-Glu, Cys-X-X-Cys), implying a simi-
lar deamination mechanism for the deaminase family
(Figure 6). There is also conservation of residues in-
volved in the binding of nucleobases substrates. The
positions of the catalytic Zn2 and water molecule in
yCD are structurally equivalent to the Zn2 and water
molecule in the CDA structures. Functionally equivalent
residues involved in coordinating the bound zinc ion in
yCD and E. coli/B. subtilis CDA are His 62:His 102/Cys53,
Cys 91:Cys 129/86, and Cys 94:Cys 132/89. Several simi-
lar residues are also involved substrate coordination: Ile
33:Val 73/26, Glu 64:Glu 104/55, Leu 88:Tyr 126/Val84,
and the main chain nitrogen of Gly 63:Ala 103/54. Three
additional residues also fulfill similar roles in coordinat-
ing the bound substrate for yCD and CDA but are signifi-Figure 3. Noncatalytic Zinc Atom within the yCD Active Site
cantly displaced in the structural superposition; theseView of yCD apo-enzyme active site with residues colored by atom
residues are Asn 51:Asn 89/42, Asp 155:Glu 91/44, andtype (not shown: Leu 88, Ile 156).
Trp 152:Phe 71/24. Additional residues on adjacent sub-(A) Anomalous Fourier synthesis map (SigmaA-weighted Fobs-
Fcalc) contoured at 8 (yellow density) showing the location of the units within the oligomeric complexes of E. coli and
bound Zn2 ions. B. subtilis CDA contribute to the hydrophobic binding
(B) Fobs-Fcalc simulated annealing omit map contoured at 4 (green pocket observed in those structures. E. coli CDA uses
density) showing the tetrahedrally coordinated noncatalytic Zn2 in
a loop from the adjacent monomer (Phe 165-Leu 170) tothe absence of bound substrate. Figures 3 and 4 were made with
sequester the hydrophobic pocket from solvent access,XtalView and Raster3D (McRee, 1999; Merritt and Bacon, 1997).
whereas B. subtilis CDA uses residues from two adja-
cent monomers (Tyr 48 subunit D, Phe 125 subunit B).
In contrast, the yCD binding pocket is completely con-from Bacillus subtilis (PDB 1JTK) (Johansson et al., 2002)
and Escherichia coli (PDB 1CTT) (Betts et al., 1994), with tained within one monomer, located behind helix 6.
Though not observed, domain movements are necessaryZ scores of 9.0 and 8.0, respectively (Figure 5A). These
two enzymes superimpose with the yCD monomer with for enzyme catalysis in for both bacterial CDA and yCD.
Despite the similarities in the yCD and CDA activermsd values of 3.0 and 3.1 A˚ for superposition of 100
and 96 C carbons, respectively. The C-terminal AICAR sites, yCD displays a high specificity for cytosine and
has no reactivity toward cytidine ribonucleoside. Dock-transformylase domain of ATIC contains three subdo-
mains, two of which (subdomains 2 and 4) have a similar ing of a cytidine ribonucleoside in the yCD binding
pocket results in steric clash of the ribose sugar withtopology. The similarity between these AICAR trans-
formylase subdomains and E. coli cytidine deaminase the 6 helix backbone and with side chains from Asn
51 and Asp 155. The decreased size of the yCD bindinghas previously been reported (Greasley et al., 2001).
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Figure 4. yCD Bound to a Mechanism-Based
Inhibitor
Stereo view of yCD inhibitor-bound active site
colored by atom type. Fobs-Fcalc simulated
annealing omit map contoured at 4 (blue
density) showing the location of the transition
state analog DHP and residues within 4A˚ of
the bound compound (not shown: Ile 156).
The map was calculated prior to the inclusion
of the ligand in the crystallographic model.
pocket contributes to specificity for the hydrophobic aminase (Figure 7A). The coordination of the active site
metal is significantly different between the two enzymenucleobase. Structural analysis shows this specificity
results from the position of the C-terminal helix observed families (Figure 7B). The zinc atom in yeast cytosine
deaminase is bound in a nearly perfect tetrahedral ar-in the yCD monomer. The C terminus of yCD is highly
conserved in amino acid sequence alignments of pre- rangement of four ligands (two cysteines, one histidine,
and a bound hydroxyl ion), whereas bacterial cytosinedicted cytosine deaminases, but is absent in alignments
with known and predicted cytidine deaminases (Figure deaminase uses an iron(II) atom coordinated in a trigonal
bipyramid arrangment to five ligands (three histidines,6). Gain or loss of this C-terminal element represents
a point of divergence between cytosine and cytidine one aspartate, and a bound hydroxyl). The mammalian
adenosine deaminase enzyme (ADA) is also formed fromdeaminases with a mixed / fold.
an ()8 barrel scaffold and contains a catalytic zinc
coordinated in a similar geometry as the iron(II) in bCD.Structural Comparison of Independently Evolved
Nucleic Acid Deaminases None of the metal binding residues in bCD or ADA have
structural homologs in the yCD or CDA active sites.The structure of yeast cytosine deaminase is completely
dissimilar from that of bacterial cytosine deaminase, A common feature of both yCD and bCD is a buried
active site contained within the enzyme monomer thatthough both act on the same nucleobase substrate.
Yeast cytosine deaminase is a homodimer with a mixed sequesters the active site from solvent, as well as im-
plied (yCD) or experimentally visualized (bCD) domain/ fold that displays homology to bacterial cytidine
deaminase. In contrast, bacterial cytosine deaminase is movements at the active site entrance during the cata-
lytic reaction. Both enzymes make extensive contactsa hexamer composed of individual subunits with an ()8
barrel fold, homologous to mammalian adenosine de- to substrate through a combination of hydrogen bonding
Figure 5. Superposition of Yeast Cytosine
Deaminase and Bacterial Cytidine Deam-
inase
(A) Stereo view of a superposition (DALI) of
yCD (gray) bound with 4-(R)-hydroxyl-3,4-
dihydropyrimidine (DHP, gray), E. coli CDA
(1CTT, slate) bound with 3,4-dihydrozebular-
ine (DHZ, slate), and B. subtilis (1JTK, green)
bound with 3,4,5,6-tetrahydro-2-deoxyuri-
dine (THU, green) shown in ribbon diagram
with bound compounds as ball and stick.
(B) Stereo view of active site residues for yCD
and E. coli CDA with bound substrates,
shown in a stick representation with yCD col-
ored by atom type with residue labels in
black, with corresponding residues and la-
bels in CDA displayed in slate.
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Figure 6. Sequence Alignment of Cytosine and Cytidine Deaminases
Multiple sequence alignment of five cytosine deaminases (Saccharomyces cerevisiae, CAA95006; Candida albicans, AAC15782; Shewanella
oneidensis MR-1, AAN54462; Thermosynechococcus elongatus BP-1, NP_681249; Xanthomonas axonopodis, NP_640992), three tetrameric
cytidine deaminases (Bacillus subtilis, P19079; Homo sapiens, AAB24946; Saccharomyces cerevisiae, ADD04031), and the catalytic domain
of two dimeric cytidine deaminases (Escherichia coli, P13652; Shewanella oneidensis MR-1, AAN55813) using ClustalW (Thompson et al.,
1994) and ESPript (Gouet et al., 1999). Symbols note conserved residues important for metal binding and catalysis (star), residues shared
between CD and CDA substrate binding (oval), and substrate binding residues specific to CD (triangle). The bar at the bottom displays the
relative accessibility of each residue for yCD, as calculated by DSSP (Kabsch and Sander, 1983). Blue indicates an accessible residue, cyan
indicates a residue with intermediate accessibility, and white indicates a buried residue.
and hydrophobic interactions. While the residues lining also appears to encompass RNA-editing adenosine de-
aminases (which bind and act on double-stranded RNAthe active site are largely different, both enzymes use
a glutamate residue for protonation during catalysis. In substrates) (Gerber and Keller, 2001). The second family
evolved from an ()8 barrel-containing ancestor, con-yCD, only one carboxylate residue is present (Glu64) to
abstract a proton from the zinc bound water and to tains both bacterial cytosine nucleobase deaminase and
adenosine ribonucleoside deaminase.protonate the N3 on the pyrimidine ring and reduce the
N3-C4 double bond character for the formation of the Currently, both bacterial and yeast cytosine deami-
nase are under active development for anticancer pro-tetrahedral intermediate. In contrast, bCD appears to
use two residues for proton extraction from the metal drug gene therapies (Cunningham and Nemunaitis,
2001; Erbs et al., 2000; King et al., 2002; Zhang et al.,bound water (Asp 314) and protonation of N3 on the
pyrimdine ring (Glu 217). The orientation of these resi- 2003). The determination of the structures of yCD and
bCD sets the stage for comparative studies of enzymedues within the respective active sites leads to opposite
enantiomeric conformations of the mechanism-based variants, derived from each protein fold, that display
increased binding and turnover of 5FC, for the purposeinhibitor (4 [R/S]-hydroxyl-3,4-dihydropyrimidine).
of antitumor-targeted gene therapy. In this clinical strat-
egy, tumor cells are transfected with a “suicide” geneConclusions
It would appear that aminohydrolase enzymes have that encodes a metabolic enzyme capable of converting
a nontoxic prodrug into a potent cytotoxin (Greco andevolved independently at least twice from separate pro-
tein fold lineages, and that binding and catalysis by Dachs, 2001). Treatment with the prodrug allows selec-
tive eradication of tumor cells while sparing normal tis-either family is not uniformly correlated with the chemi-
cal differences between purine or pyrimidine, nucleo- sue from significant cell killing. The therapeutic effect
in the tumor bed is dictated by several variables, includ-base or nucleoside, or DNA or RNA substrates. One
deaminase family containing yeast cytosine deaminase ing the efficiency of prodrug turnover.
The comparison of yCD and bCD active sites explainsand cytidine ribonucleoside deaminase evolved from a
common mixed / ancestor. This protein fold family the higher affinity for the alternate substrate 5FC ob-
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Figure 7. Structural Comparison of Yeast and Bacterial Cytosine Deaminase
Ribbon diagram for monomeric structures with  helices colored green,  strands colored blue, and random coil in yellow, and catalytic ions
(yCD Zn2, violet; bCD Fe2, red) for (A) yCD and (B) bCD (prepared with Ribbons) (Carson, 1997). The bCD ()8 barrel is the lower domain;
the bound metal ion (red sphere) is visible at one end of the barrel pore axis. The N- and C-terminal ends of the protein fold together to form
the  sandwich domain (top of the ribbon diagram) and a domain-swapped C-terminal arm that participates in dimerization. Helices 1 and
8 protrude from the barrel fold and form flaps that border the entrance to the enzyme active site. Active site comparison of (C) yCD and (D)
bCD bound with DHP, shown in stick representation. Dashed lines represent the nearest contact of active site residues to the C5 atom on
the pyrimidine ring.
served for the yeast enzyme (Kievit et al., 1999). In yCD, meric packing, thermal stability, and kinetic parameters
while catalyzing the same reaction, these studies willthe nearest protein side chain to the C5 carbon on DHP
provide significant insight into the relative aspects ofis hydrophobic (Phe 114, 4.0 A˚), whereas in bCD it is
protein structure and function that are crucial for geneelectronegative (Asp 314, 3.6 A˚). The presence of fluorine
therapy applications.on the C5 carbon of the pyrimidine ring would therefore
be less tolerated for bCD due to electrostatic repulsion.
Experimental ProceduresMutation of bCD Asp 314 to alanine results in a 10-fold
increase in 5FC turnover for the bCD enzyme (our un- Cloning and Expression
published data). Because bacterial and yeast cytosine Polymerase chain reaction was used to amplify the FCY1 gene (yCD)
from pRS306-FCY1, a kind gift from Dr. Jean Emmanuel Kurtz anddeaminase differ dramatically in size, sequence, oligo-
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Dr. Richard Jund (Strasbourg, France), to introduce an NcoI site at 0.15  0.3 mm rods in 5–7 days, and diffracted to 	1.1 A˚ with low
mosaicity (0.25) and no anisotropy. Crystals were flash cooled forthe start codon (Erbs et al., 1997). A 490 bp NcoI/HinDIII fragment
containing the yCD gene was subcloned into pETHT restricted with data collection after sequential transfers in buffer containing 5%
DMSO to a final artificial mother liquor containing 25% DMSO, 25%the same enzymes. The resulting plasmid was confirmed by se-
quencing and designated pETHT:yCD. This plasmid was obtained PEG 8000, 0.1 M sodium cacodylate (pH 6.5), and 0.1 M calcium
acetate.from Margaret Black and subcloned into pET15b (Novagen, Darm-
stadt, Germany) using XbaI-XhoI and transformed into E. coli strain X-ray diffraction data for the initial structure determination were
collected to 1.4 A˚ resolution, with spots visible to at least 1.1 A˚,BL21-RIL(DE3) (Novagen). Cells expressing pET15b-yCD were
grown in Luria broth media at 37C to an OD600 of 0.7, induced with from crystals containing selenomethionine-derivatized protein at
beam line 5.0.2 at the ALS (Advanced Light Source, Lawrence Berke-0.5 mM IPTG and supplemented with 0.5 mM zinc acetate, and
grown overnight at 16C. The cells were harvested by centrifugation ley Laboratory, Berkeley, CA) using a four panel ADSC CCD area
detector. Data were collected at a wavelength corresponding to theat 2000 g for 10 min at 4C, and the cell pellets were resuspended
in 50 ml lysis buffer (300 mM NaCl, 20 mM Tris-HCl, pH 7.0, 5 mM selenium K-edge (peak) in order to determine the structure of the
enzyme using the single anomalous dispersion (SAD) techniqueImidazole, 0.2% Triton X-100, 0.5 mM PMSF) and lysozyme added
to 0.5 mg/ml, followed by 30 min incubation on ice. Cells were (Hendrickson, 1991). The crystals belong to the space group P212121,
with unit cell parameters a 
 53.48 A˚, b 
 70.50 A˚, c 
 71.70 A˚.sonicated using a Branson Sonifier 250 equipped with a macrotip
set to pulse for 5–8 min at 4C with the duty cycle set to 40%. The The asymmetric unit contained a dimer giving a Matthews coefficient
VM of approximately 1.95 A˚3/Da1, corresponding to a solvent con-cell lysate was clarified by centrifugation at 20,000  g for 30 min
at 4C, and the clarified supernatant was passed through a 0.45 m tent of 35% (Matthews, 1968).
Data were processed and scaled using the DENZO/SCALEPACKsyringe filter.
The filtered supernatant was added to 5 ml packed bed volume program packages (Otwinowski, 1993; Otwinowski and Minor, 1997).
The 14 selenium sites in the asymmetric unit were determined, andof TALON metal affinity resin (Clontech, Palo Alto, CA) equilibrated
with 10 bed volumes of lysis buffer, and incubated at 22C for 30 experimental phases calculated and refined, using program CNS
with a random 5% of the data excluded for the purpose of cross-min with rocking at 10 rpm. The affinity resin was washed 3 with
10 bed volumes wash buffer (300 mM NaCl, 20 mM Tris-HCl, pH validation (Brunger, 1993; Brunger et al., 1998). Statistics from phas-
ing and refinement are provided in Table 1. The initial electron density7.0, 10 mM Imidazole, 0.5 mM PMSF), and the YCD protein was
eluted from the resin with 3  15 ml elution buffer (150 mM NaCl, map was easily interpretable, and all 158 residues of each monomer
within the asymmetric unit were manually built using XtalView100 mM Imidazole, 20 mM Tris-HCl, pH 8.0). The eluted fractions
were pooled and concentrated using an Amicon pressure cell with (McRee, 1999). Electron density corresponding for 3 residues (Gly-
Ser-Ser) remaining on the yCD N terminus after thrombin cleavagea 10 kDa cutoff and dialyzed into cleavage buffer (150 mM NaCl,
20 mM Tris-HCl, pH 8.3). Thrombin cleavage of the N-terminal histi- of the N-terminal histidine tag was also observed for one of the two
monomers. The structure was refined using CNS, with a randomdine tag was conducted for 2 hr at 23C using 0.5 U biotinlyated
thrombin (Novagen) per milligram yCD protein in thrombin cleavage 5% of the data excluded for the purpose of cross-validation to an
Rwork/Rfree of 16.3/17.9 (Brunger, 1993).buffer (150 mM NaCl, Tris-HCl, pH 8.3, 2.5 mM CaCl2). Biotinylated
thrombin was removed by 30 min incubation at 23C with 20 l Native yCD crystals containing the bound DHP were grown by
streak seeding into preequilibrated drops as described above, withstreptavidin-conjugated agarose beads (Novagen) per unit thrombin
followed by gravity flow through column purification. Cleaved yCD 25 mM DHP present in the well solution. X-ray diffraction data were
collected to 1.14 A˚ (half corner) at ALS beamline 5.0.2. Data werewas loaded onto to a Superdex 200 HiLoad16/60 sizing column
(Pharmacia, Uppsala, Sweden) equilibrated with 50 mM NaCl, 25 processed and scaled using the DENZO/SCALEPACK program
packages, and refined using CNS to a resolution of 1.5 A˚, giving anmM Tris-HCl, pH 7.5, and 1 mM EDTA. Peak yCD fractions were
analyzed by SDS-PAGE, then pooled and concentrated to 10–15 Rwork/Rfree of 17.5/19.8. The model was refined against data from 10
to 1.14 A˚ resolution using SHELX (Sheldrick and Schneider, 1997),mg/ml, with yields of 30–45 mg of yCD (99%) obtained per liter of
bacterial culture. with the inclusion of individual anisotropic B factors, modeling multi-
ple conformations for 16 side chains, and the placement of hydro-For production of selenomethionine derivitized protein (Semet-
yCD), pET15b-yCD was expressed in minimal media from E. coli gens, to give a final Rwork/Rfree of 11.0/15.2.
strain in BL21-RIL (DE3) adapted for growth with methionine path-
way inhibition (Doublie, 1997). Cells were grown in minimal media Acknowledgments
at 37C to an OD600 of 0.7, and the following amino acids were added
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